iTOC6 CONFERENCE

6TH IMMUNOTHERAPY OF CANCER CONFERENCE

THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE

CDDF Cancer Drug Development Forum

sitc Society for Immunotherapy of Cancer

6TH EDITION
APRIL 11-13, 2019
VIENNA, AUSTRIA

PROGRAMME

www.itoc-conference.eu

TABLE OF CONTENTS

This is an ESO recommended event.

WELCOME LETTER

Welcome to the sixth edition of the Immunotherapy of Cancer Conference (ITOC6), the premier meeting for education, scientific exchange and networking within cancer immunotherapy.

The scientific programme with an international faculty will focus on many topics such as Microenvironment and metabolism, Emerging concepts / novel agents, Checkpoint inhibition and resistance mechanisms, Combination therapy, Cell therapy, Monitoring of immunotherapy, Update on clinical breakthroughs.

Organised by the Cancer Drug Development Forum (CDDF), whose mission is to provide a unique platform to facilitate interactions between all stakeholders (academia, regulatory authorities, policymakers, industry, patient advocacy groups and health technology assessors) to improve the efficiency of cancer drug development and in cooperation with Society for Immunotherapy of Cancer (SITC), the ITOC conference series aim to provide a forum for discussion of early clinical drug development and address its unique challenges.

The conference offers a broad and exciting range of opportunities and tools to gain exposure to experts in various disciplines within Europe and far beyond, and we wish you a very successful and enjoyable ITOC6 in the beautiful city of Vienna.

In addition, we wish to express our sincere gratitude to the entire committee, organising partners and sponsors and exhibitors.

Your ideas and suggestions on the future of this conference are welcome. We therefore encourage you to complete the online survey after the conference and please do not hesitate to reach out to our team on site or via email (itoc@medacad.org)

Yours sincerely,

Prof. Dr. Christoph Zielinski
Conference President

Prof. Dr. Mario Sznol
Conference President

Prof. Dr. Volkmar Nüssler
Munich Tumour Center

Prof. Heinz Zwierzina
Scientific Chairman

CANCER DRUG DEVELOPMENT FORUM

CDDF provides a unique forum where all those dedicated to the development of cancer drugs can exchange expertise to find ways to expedite effective oncology drug development and delivery.

For the past years, CDDF has strived to leverage the discussion of the most promising advances in oncology drug development, uniting experts from academia, pharmaceutical industry and regulatory authorities in the quest of overcoming the main challenges in cancer treatment.

Meeting reports and publications based on previous workshops and events are featured in some of the leading oncology journals. You may access CDDF's list of publications at: www.cddf.org

ORGANIZING PARTNERS

ITOC6 POSTER PRIZE

We are proud to announce the ITOC6 Poster Prize which will be awarded at the 6th Immunotherapy of Cancer Conference thanks to the generous support of the Tumor Center Munich.

Prizes will be awarded to the three best poster presentations. The winners will receive a certificate and a prize of EUR 1000,-/700,-/500,-.

Winners are selected by the scientific committee according to the following criteria:

- Scientific content/methodology
- Novelty and originality of research
- Ability of the author to present the poster in a concise and clear manner and to answer questions during the dedicated poster sessions.

Poster reviewing-Committee:

- Chairman: Sebastian Kobold (Ludwig-Maximilians-Universität, Germany)
- Zihai Li (Medical University of South Carolina, United States)
- Volkmar Nuessler (Munich Tumour Center, Germany)
- Eric Tartour (Hôpital Européen Georges-Pompidou, France)

CONFERENCE COMMITTEE

CONFERENCE PRESIDENTS

- Mario Sznol (Yale School of Medicine, New Haven, CT, United States)
- Christoph Zielinski (Medical University of Vienna, Austria)

CHAIRMAN OF THE SCIENTIFIC COMMITTEE

- Heinz Zwierzina (Innsbruck University, Austria)

SCIENTIFIC COMMITTEE

- Paolo Ascierto (Istituto Nazionale Tumori, Italy)
- Michael Bergmann (Medical University of Vienna, Austria)
- Lisa Butterfield (Parker Institute for Cancer Immunotherapy, United States)
- John Haanen (Netherlands Cancer Institute, The Netherlands)
- Leif Hakansson (Universitetssjukhuset Linköping, Sweden)
- Samir N. Khleif (Georgia Regents University, United States)
- Sebastian Kobold (Ludwig-Maximilians-Universität, Germany)
- Zihai Li (Medical University of South Carolina, United States)
- Volkmar Nuessler (Munich Tumour Center, Germany)
- Pedro J. Romero (University of Lausanne, Switzerland)
- José Saro (Avacta Life Sciences, United Kingdom)
- Barbara Seliger (Martin Luther University Halle-Wittenberg, Germany)
- Wenru Song (Kira Pharmaceuticals, United States)
- Eric Tartour (Hôpital Européen Georges-Pompidou, France)
- Michael von Bergwelt (Klinikum der Universität München, Germany)
- Dominik Wolf (Innsbruck University, Austria)
- Lei Zheng (Johns Hopkins University, Baltimore, MD, United States)

ACCREDITATION FOR CONTINUOUS MEDICAL EDUCATION (CME)

The 6th ImmunoTherapy of Cancer Conference, Vienna, Austria (April 11 – 13, 2019) has been granted 15 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

European Accreditation is granted by the EACCME in order to allow participants attending the above mentioned activity to validate their credits in their own country.

PROGRAMME AT A GLANCE

THURSDAY, APRIL 11, 2019

09.00	Registration Opens
11.00 – 11.10	Welcome Address
11.10 – 11.30	Opening Lecture - Immunotherapy – next challenges of clinical drug development
11.30 – 13.10	Plenary Symposium 1 – Microenvironment and metabolism
13.10 – 14.10	Lunch
14.10 – 15.50	Plenary Symposium 2 – Emerging Concepts / New Agents
15.50 - 16.30	Coffee Break
16.30 - 18.20	Plenary Symposium 3 – Combination Therapy
18.20	Welcome Reception and Poster Viewing

FRIDAY, APRIL 12, 2019

08.30 – 09.30	TNBC (Triple Negative Breast Cancer) Meet the Expert Session
09.30 – 10.30	Plenary Symposium 4 – Preclinical Models
10.30 – 11.00	Coffee Break
11.00 – 12.40	Plenary Symposium 5 – Precision Medicine Meets Immunotherapy
12.45 - 13.15	Exhibitors (Pipeline) Session
13.15 – 14.00	Lunch
14.00 – 14.30	Poster Session with Presenters
14.30 – 15.15	Lifetime Achievement Award
15.15 – 15.45	Coffee Break
15.45 – 17.15	Plenary Symposium 6 – Cell Therapy
17.15 - 17.55	Plenary Session 7 – Young Researcher Session
19.30	ITOC6 Conference Dinner

SATURDAY, APRIL 13, 2019

08.30 – 09.30	Plenary Symposium 8 – Anticancer vaccines
09.30 – 11.10	Plenary Symposium 9 – Clinical Breakthrough with Immunotherapy - Part 1
11.10 – 11.40	Coffee Break
11.40 - 12.40	Plenary Symposium 9 – Clinical Breakthrough with Immunotherapy - Part 2
12.40 - 13.00	Best Poster Awards & Closing Remarks
13.00 – 14.00	Lunch

SCIENTIFIC PROGRAMME

THURSDAY, APRIL 11, 2019

09.00	Registration Opens
11.00 – 11.10	**Welcome Address** Christoph Zielinski, Vienna, Austria
11.10 – 11.30	**Opening Lecture - Immunotherapy – next challenges of clinical drug development** Mario Sznol, New Haven, CT, USA
11.30 – 13.10	**Plenary Symposium 1 – Microenvironment and metabolism** Chair: Mario Sznol, Christoph Zielinski
11.30 – 11.50	Imaging of T cell success and failure within the tumor microenvironment Emmanuel Donnadieu, Paris, France
11.50 – 12.10	Role of TGFß and CAFs in T cell exclusion Eduard Batlle, Barcelona, Spain
12.10 - 12.30	Checkpoint inhibition and metabolic reprogramming Bo Huang, Beijing, China
12.30 – 12.50	Role of intratumoral memory T cells for immune surveillance Pedro Romero, Lausanne, Switzerland
12.50 – 13.10	Microbiota and its role for response to immunotherapy Lisa Derosa, Villejuif, France
13.10 – 14.10	Lunch
14.10 – 15.50	**Plenary Symposium 2 – Emerging Concepts / New Agents** Chair: Samir Khleif, Pedro Romero
14.10 – 14.30	Targeting the CD73-adenosine axis for immunotherapy Paolo Ascierto, Naples Italy
14.30 - 14.50	Modulation of checkpoint antibodies Ana Anderson, Boston, MA, USA
14.50 - 15.10	Leukemic stem cells and immune evasion Claudia Lengerke, Basel, Switzerland
15.10 - 15.30	NK cells as target for therapeutic intervention Stéphanie Cornen, Marseille, France
15.30 - 15.50	The Siglec pathway - a target for improving T-cell activation Heinz Läubli, Basle, Switzerland
15.50 - 16.30	Coffee Break
16.30 - 18.20	**Plenary Symposium 3 – Combination Therapy** Chair: Paolo Ascierto, Michael Bergmann
16.30 - 16.50	Rationales for combination strategies Samir Khleif, Augusta, GA, USA
16.50 - 17.10	Combination of checkpoint inhibition and vaccines Sjoerd van der Burg, Leiden, The Netherlands
17.10 - 17.30	Interaction between cytokines and checkpoint inhibitors Aaron Ring, New Haven, CT, USA
17.30 - 17.50	Combination of Oncolytic Viruses and Checkpoint Inhibitors Alan Melcher, London, United Kingdom
17.50 - 18.10	Histon-Deacetylase inhibition in combination with immunotherapy Alfredo Budillon, Naples, Italy
18.10 - 18.20	02 Overall responses and survival in RCC on Pegilodecakin with anti-PD-1 Aung Naing, Houston, TX, United States
18.20	Welcome Reception and Poster Viewing

FRIDAY, APRIL 12, 2019

08.30 – 09.30	**TNBC (Triple Negative Breast Cancer) Meet the Expert Session** Please see page 19 for details
09.30 – 10.30	**Plenary Symposium 4 – Preclinical Models** Chair: Eric Tartour, Lei Zheng
09.30 – 09.50	Tumor organoids and immune cells Emile Voest, Amsterdam, The Netherlands
09.50 – 10.10	Analysis of the tumor microenvironment by single cell analysis Bernard Thienpont, Leuven, Belgium
10.10 – 10.30	In vivo imaging of immune responses using PET-CT Angela Krackhardt, Munich, Germany
10.30 – 11.00	Coffee Break
11.00 – 12.40	**Plenary Symposium 5 – Precision Medicine Meets Immunotherapy** Chair: Heinz Zwierzina, Zihai Li
11.00 – 11.20	Challenges of including immunobiomarkers into clinical drug development Jeffrey Weber, New York, NY, USA
11.20 – 11.40	Circulating tumor DNA as a tool to predict response in immunotherapy François-Clément Bidard, Paris, France
11.40 – 12.00	T Cell subpopulations predict response to combination of PD-L1 blockage and chemotherapy Barbara Seliger, Halle, Germany
12.00 - 12.20	Prediction of efficacy and toxicity of immunotherapeutic agents Lei Zheng, Baltimore, MD, USA
12.00 – 12.20	System immunology and tumor microenvironment Jerome Galon, Paris, France
12.20 – 12.30	03 A plasma-based assay for assessment of tumour mutational burden in patients with metastatic non-small cell lung cancer in the first-line treatment setting: results from the MYSTIC study Han Si, Gaithersburg, MD, United States
12.30 - 12.40	04 Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in non-small cell Lung carcinoma patients responding to atezolizumab treatment Alessandra Nardin, Singapore, Singapore
12.45 - 13.15	**Exhibitors (Pipeline) Session** Please see page 20 for details
13.15 – 14.00	Lunch
14.00 – 14.30	**Poster Session with Presenters** Chair: Sebastian Kobold, Zihai Li, Volkmar Nüssler, Eric Tartour
14.30 – 15.15	**Lifetime Achievement Award** Chair: Christoph Zielinski Innate Immunity, Inflammation and Cancer: from bench to bedside Alberto Mantovani, Milan, Italy
15.15 – 15.45	Coffee Break
15.45 – 17.15	**Plenary Symposium 6 – Cell Therapy** Chair: Lisa Butterfield, Michael von Bergwelt
15.45 - 16.05	Next generation cell therapies Lisa Butterfield, San Francisco, CA, United States
16.05 - 16.25	TRUCKs Hinrich Abken, Regensburg, Germany
16.25 - 16.45	Synthetic agonist receptor modified T cells: a new modular platform for T-cell therapy Sebastian Kobold, Munich, Germany
16.45 - 17.05	CAR-NK cell therapy Ulrike Koehl, Leipzig, Germany
17.05 - 17.15	05 Characterization of bispecific antibodies that drive synthetic agonistic receptor - transduced T Cells to mediate specific and conditional therapy in human pancreatic cancer models Mohamed-Reda Benmebarek, Munich, Germany
17.15 - 17.55	**Plenary Session 7 – Young Researcher Session** Chair: Sebastian Kobold
17.15 - 17.25	06 A screening for novel immune-checkpoints identifies a serine/threonine kinase to confer Immune resistance in multiple myeloma Valentina Volpin, Regensburg, Germany

17.25 - 17.35	07 Immune and mutational landscape in triple negative breast cancer and its evolution during neoadjuvant chemotherapy associated or not with GTN and anti-PD-1 Nesrine Mabrouk, Dijon, France
17.35 - 17.45	08 In-situ diversification of immunity following vaccination targeting tumor neoepitopes; an integral component of combinatorial immunotherapy Karin Lee, Bethesda, MD, United States
17.45 - 17.55	09 Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis Julijan Kabiljo, Vienna, Austria
19.30	ITOC6 Conference Dinner

SATURDAY, APRIL 13, 2019

08.30 – 09.30	**Plenary Symposium 8 – Anticancer vaccines** Chair: Cornelis Melief, Barbara Seliger
08.30 – 08.50	Challenges of anticancer vaccine development Cornelis Melief, Leiden, The Netherlands
08.50 - 09.10	Mimotopes for Vaccination against Cancer Ursula Wiedermann-Schmidt, Vienna, Austria
09.10 - 09.30	Neoantigen vaccination David Reardon, Boston, MA, United States
09.30 – 11.10	**Plenary Symposium 9 – Clinical Breakthrough with Immunotherapy - Part 1** Joint Session with ESMO Chair: John Haanen, Paul Nathan
09.30 – 09.50	Immune related adverse events Michael von Bergwelt, Munich, Germany
09.50 – 10.10	Cell Therapy John Haanen, Amsterdam, The Netherlands
10.10 - 10.30	Checkpoint inhibition in hematological malignancies Dominik Wolf, Innsbruck, Austria
10.30 - 10.50	Lung (NSCLC) Rudolf-Maria Huber, Munich, Germany
10.50 - 11.10	Melanoma Helen Gogas, Athens, Greece
11.10 – 11.40	Coffee Break
11.40 - 12.40	**Plenary Symposium 9 – Clinical Brea rough with Immunotherapy - Part 2** Joint Session with ESMO Chair: Volkmar Nüssler, Michael von Bergwelt
11.40 – 12.00	Immunotherapy for GI Cancers - MSI and beyond Volker Heinemann, Munich, Germany
12.00 - 12.20	Renal Cancer Paul Nathan, London, United Kingdom
12.20 - 12.40	Head & Neck Marco Merlano, Cuneo, Italy
12.40 - 13.00	**Best Poster Awards & Closing Remarks**
13.00 – 14.00	Lunch

POSTER PRESENTATIONS

TOPIC 1
MICROENVIRONMENT AND METABOLISM

P1.1 LL-37 inhibits pancreatic cancer development through inhibition of autophagy and reprogramming of the tumor microenvironment
Joshua Ko, Kowloon Tong, Hong Kong

P1.2 Tissue Slice Culture Platform: A Slice of Reality in Drug Development
Fabien Garcon, Cambridge, United Kingdom

P1.3 Omental fat in ovarian cancer induces lymphangiogenesis – The role of an adipose-rich microenvironment in tumor progression and metastatic dissemination.
Victor Starrach, Heidelberg, Germany

P1.4 Reprogramming of M2-like macrophages to M1-like phenotype by tumor-antigen specific CD4+ T cells
Stefan Eichmüller, Heidelberg, Germany

P1.5 Myeloid cells mediates the accelerated growth of tumor in high-fat diet-fed mice
Thi TRAN, Paris, France

P1.6 The panta rhei of breast cancer: gene expression timeline analysis during progression of microinvasive breast cancer microenvironment
Francesca Lessi, San Giuliano Terme, Italy

P1.7 Immunogenic effects of FOLFOXIRI plus Bevacizumab therapy in colorectal peritoneal carcinomatosis
Monika Sachet, Vienna, Austria

P1.8 Differences in macrophage colonization of the colorectal cancer and normal mucosa
Natalie Walterskirchen, Vienna, Austria

P1.9 Comparing the immune cell infiltration of colorectal cancer with distant normal mucosa uncovers a prognostically relevant immune cell profile
Rudolf Oehler, Vienna, Austria

P1.10 Probing the interaction of macrophages in the pancreatic cancer microenvironment using 3D engineered rollable tumour (TRACER)
Ileana Co, Toronto, Canada

P1.11 Abstract withdrawn

P1.12 Cholesterol induces CD8+ T-cell exhaustion in the tumor microenvironment
Qing Yi, Houston, United States

P1.13 Establishing of a primary cancer microtissue model to investigate immune cell infiltration
Stefan Koeck, Innsbruck, Austria

P1.14 The nonessential amino acid proline enhances migration and proliferation of human melanoma cells
Konstantin Mayr, Vienna, Austria

P1.15 Glycosylation of the cytokine co-receptor gp130 reveals a rapid protein turnover, which gives raise to biased signalling in human melanoma cells from different disease stages
Katharina Svoboda, Vienna, Austria

P1.16 Lipid-storing, tumor-associated macrophages orchestrate a tumor-excluded immune landscape in omentum metastases of epithelial ovarian cancer.
Meggy Suarez-Carmona, Heidelberg, Germany

P1.17 Clearance of apoptotic bodies by neutrophils induce tissue regenerative responses
Victoria Brandel, Vienna, Austria

P1.18 Cancer associated mast cells exhibit a tumor promoting phenotype but can be effectively targeted to reinvigorate antitumor immunity in a human based ex-vivo model
Dyke Ferber, Heidelberg, Germany

TOPIC 2
EMERGING CONCEPTS / NOVEL AGENTS

P2.1 Multispectral imaging for quantitative and compartment specific immune profiling of cancer tissue
Bjoern Wendik, Rodgau, Germany

P2.2 Induction of tumor-specific immune responses by the TLR9 agonist EnanDIM in murine syngeneic tumor models
Barbara Volz, Berlin, Germany

P2.3 Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on tumor cells
Eric Hatterer, Plan les ouates, Switzerland

P2.4 3D micro-tumors for predicting individual treatment responses to immunotherapy
Tabea Sturmheit, Hamburg, Germany

P2.5 HDAC6 inhibitor ITF3791 enhances alloantigen presentation capabilities of myeloid cells modulating PD-L1 expression and co-stimulatory molecules
Chiara Ripamonti, Cinisello Balsamo, Italy

P2.6 Induction of a strong and persistent antitumor immune response using liposomal vaccines in the HPV-transformed orthotopic lung tumor model TC-1
Sylvie Fournel, Illkirch, France

P2.7 Oncolysis dominated therapeutic effect of LCMV-GP – pseudotyped vesicular stomatitis virus in a syngeneic lung cancer model
Liesa-Marie Schreiber, Innsbruck, Austria

P2.8 Expression of Indoleamine 2,3-dioxygenase in erlotinib-treated patients with advanced pancreatic cancer: translational results from a multi-center, randomized phase III trial.
Stephan Kruger, Munich, Germany

P2.9 Prevention of tumor ulceration in mice – Mammary fat pad injection of tumor cells
Bettina Stahnke, Freiburg, Germany

P2.10 Abstract withdrawn

P2.11 Immune-related effects of the ETS factor inhibitor YK-4-279
Dina Baier, Vienna, Austria

P2.12 Mechanism of Action of NKTR-214, a first-in-class, CD122-preferential IL-2 pathway agonist
Willem Overwijk, Houston, United States

P2.13 The phytochemicals Curcumin and Vitamin C act as immunosensitizer
Barbara Mayer, Munich, Germany

P2.14 An oncolytic influenza A virus expressing the mycobacterial ESAT-6 protein
Viktoria Lazlo, Vienna, Austria

TOPIC 3
CHECKPOINT INHIBITION AND RESISTANCE MECHANISMS

P3.1 Development of an in vitro 3D model system for testing PD-1/ PDL-1 immune checkpoint inhibitors
Francesca Chiovaro, Zurich, Switzerland

P3.2 Interlaboratory variation in PD-L1 positivity in non-small cell lung cancer patients: a nationwide study
Bregje Koomen, Utrecht, Netherlands

P3.3 MiRNA deregulation can contribute to breakdown of MHC I class antigen processing and presenting machinery in breast cancer cells
Volodymyr Halytskiy, Kiev, Ukraine

P3.4 Modulated electro hyperthermia as an immune modulator with checkpoint inhibitors and radiotherapy
Carrie Minnaar, Johannesburg, South Africa

P3.5 Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma
Emma de Ruiter, Utrecht, Netherlands

P3.6 Study of IDO1 gene expression in histological variants of colorectal carcinoma
María Turpín Sevilla, Pozuelo de Alarcón, Spain

TOPIC 4
COMBINATION THERAPY

P4.1 Phase I trial of combination dendritic vaccine and immune checkpoint blockade for prevention of postoperative glioblastoma recurrence
Ling Chen, Beijing, China

P4.2 Characterisation of peripheral blood mononuclear cells in patients with combination ipilimumab and nivolumab therapy-related colitis.
Sarah Sasson, Oxford, United Kingdom

P4.3 Complete response of stage IV pancreatic cancer combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia
Ralf Kleef, Vienna, Austria

P4.4 Abstract withdrawn

P4.5 Abstract Withdrawn

P4.6 PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer
Mohanad Nada, Sulymanyaha, Iraq

P4.7 Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis
Diana Groza, Vienna, Austria

TOPIC 5
CELL THERAPY

P5.1 Conversion of AML-blasts to leukemia-derived dendritic cells (DCleu) in 'DC-culture-media' shifts the (serum) chemokine-release profile to a more 'inflammatory' (in culture) going along with improved antileukemic T-cell-reactivity
Marion Merle, Munich, Germany

P5.2 Arming T cells with C-X-C-motive receptor 6 enhances infiltration of pancreatic cancer patient-derived organoids
Justyna Ogonek, Munich, Germany

P5.3 A novel modular platform for adoptive T cell therapy combining bispecific antibodies with synthetic agonistic receptors
Clara Karches, München, Germany

P5.4 Arming T cells with C-X-C-motive receptor 6 enables adoptive T cell therapy of pancreatic cancer
Stefanie Lesch, Munich, Germany

P5.5 Tumor-specific immune responses after short-term BRAF-inhibitor induction in patients with melanoma resistant to checkpoint inhibitors
Aishwarya Gokuldass, Herlev, Denmark

P5.6 Anti-hPSMA CAR engineered NK-92 cells: An Off-The-Shelf cellular therapeutic for targeted elimination of prostate cancer cells
Gaia Zuccolotto, padova, Italy

TOPIC 6
MONITORING OF IMMUNOTHERAPY

P6.1 Differential analysis of complex immune biology in MSI and MSS colorectal tumor microenvironments using high-plex spatial resolution
Douglas Hinerfeld, Seattle, United States

P6.2 Abstract withdrawn

P6.3 Modulation of AML-blasts with clinically approved response modifiers to leukemia-derived dendritic cells(DCleu) ex vivo: DC-, T-cell- and cytokine profiles are predictive for antileukemic T-cell reactivity
Helga Schmetzer, Munich, Germany

P6.4 Human lung cancer explants model: set up of a predictive model for treatment
Benedicte Lenoir, Heidelberg, Germany

P6.5 Increased detection of (leukemiaspecific) adaptive and innate immune-reactive cells under treatment of AML-diseased rats and one therapy-refractory AML-patient with blastmodulating, clinically approved response modifiers
Michael Atzler, Munich, Germany

P6.6 Clinical relevance of in vitro generated dendritic cells of leukemic origin to predict response to immunotherapy in patients with AML and MDS
Markus Freudenreich, Munich, Germany

P6.7 T cell repertoire convergence and clonal expansion in cytomegalovirus infection : implications for the biomarker use of TCR-seq
Timothy Looney, Austin, United States

P6.08 Monitoring the effect of immunomodulatory treatment on the immune repertoire using the IGX platform
N. Bonzanni, 's-Hertogenbosch, The Netherlands

TOPIC 7
YOUNG RESEARCHER SESSION

P7.1 morphological consequences for noncapsular lymphoid tissue in the case of malignancy of GERD
Bakhtiyar Azhken, Astana, Kazakhstan

P7.2 Interleukin-37b exerts antitumor activity on gallbladder cancer cell line
Nichapa Lerthirunvibul, Pathumthani, Thailand

P7.3 Tumour-infiltrating lymphocytes influence prognosis in Human Papillomavirus-positive cervical and oropharyngeal cancer: A systematic review
Christian Anderson, Liverpool, United Kingdom

P7.4 Effects of the tumor microenvironment generated by glioblastoma multiforme cells over monocyte-derived dendritic cells
Nadia Emely Chauca Torres, Sao Paulo, Brazil

P7.5 Innovative antitumoral platinum (II) compounds as chemotherapeutic and immunotherapeutic agents
May Wantz, Illkirch Cédex, France

P7.6 Breast cancer patients have multifunctional tumor-reactive CD4 T cells in both blood and tumor
Mariana Pinho, São Paulo, Brazil

P7.7 Stress granule Y-box-binding protein 1 predicts prognosis in colorectal liver metastases independent and superior to DNA damage
Andreas Winter, Vienna, Austria

P7.8	Irradiated cancer exosomes promote M1-like polarization of macrophages and enhance their anti-tumoral responses *Victoria Stary, Vienna, Austria*
P7.9	Parasites and immunotherapy: immunostimulatory effect of Leishmania spp. in cancer treatment *Mumin Alper Erdogan, Izmir, Turkey*
P7.10	Overshooting Neutrophil Attraction by Osteopontin Inhibits Liver Regeneration after Partial Hepatectomy *David Pereyra, Vienna, Austria*
P7.11	Role of B lymphocytes in two types of precancerous liver diseases (PLD) *Nataliia Petriv, Hannover, Germany*

FLOORPLAN (ATRIUM)



COMPANY NAME	STAND #
10X Genomics	10
Agilent Technologies	6
AID	11
Akoya Biosciences	21
BIOZOL	19
CeGaT	5
ENPICOM	14
Fluidigm	4
Immudex	2
Indica Labs	7
Metabolon	1
NanoString Technologies	3
OriGene Technologies	12
Quanterix	13
SITC	8
Thermo Fisher Scientific	9
ULTIVUE	20

ACKNOWLEDGMENTS

GRANT DONATORS / SPONSORS / EXHIBITORS / PARTNERS

For questions regarding sponsorship and exhibition, please contact Rose International.

- Contact: Flora van Laer
- E-mail: fvanlaer@rose-international.com
- Telephone: +31 70 383 89 01

We thank all ITOC6 grant donors, sponsors, exhibitors and partners.

The ITOC6 Organising Committee wishes to gratefully acknowledge our grant donors, sponsors, exhibitors and partners for supporting the 6th Immunotherapy of Cancer Conference (ITOC6).

GRANT DONATORS

Supported by independent educational grants from:

- AbbVie
- Celgene International
- Gilead Sciences Europe Ltd
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
- Novartis
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

SPONSORS

Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

View more at www.roche.com

AKOYA BIOSCIENCES

Akoya Biosciences offers comprehensive solutions for multiplexed immunofluorescence that span the journey from biomarker discovery to validation. Founded in 2015, Akoya has an exclusive license to commercialize the CODEX® benchtop platform which can image 40+ tissue biomarkers using existing fluorescence microscopes. In October 2018, Akoya Biosciences acquired the Phenoptics™ business of PerkinElmer, which includes the Vectra® Polaris™ system for high throughput multiplexed immunofluorescence.

View more on www.akoyabio.com

FLUIDIGM

Fluidigm is committed to empowering the cancer immunotherapy community with research tools to interrogate the tumor microenvironment with unprecedented resolution. Whether you seek to target new biomarkers or to optimize the effectiveness of checkpoint inhibitors, CAR T cells or cancer vaccines, Fluidigm can help you reach your next research breakthrough.

View more on www.fluidigm.com

NanoString Technologies

NanoString® Technologies provides life science tools for translational research and molecular diagnostic products. The Company's proprietary nCounter® Analysis System offers simultaneous analysis of RNA, DNA, and protein expression with high sensitivity and precision. NanoString collaborates with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

View more on nanostring.com

EXHIBITORS

10x Genomics

10x Genomics, Inc. is building tools for scientific discovery that reveal and address the true complexities of biology and disease. Through a combination of novel microfluidics, chemistry and bioinformatics, our award-winning Chromium System is enabling researchers around the world to more fully understand the fundamentals of biology at unprecedented resolution and scale. #GOEXPONENTIAL

View more on www.10xGenomics.com

Agilent Technologies Österreich GmbH

Agilent Technologies Inc. is a global leader in life sciences, diagnostics and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers' most challenging questions. Agilent employs about 13,500 people worldwide.

View more on www.agilent.com/chem

AID GmbH

AID GmbH is a German family-owned life science and diagnostics company, founded in 1989. AID GmbH develops, manufactures, and globally markets automated Reader Systems and a wide range of IVD/CE marked assays for EliSpot/FluoroSpot, molecular diagnostics and serology. The versatile AID Reader Systems cope with colorimetric and fluorometric assays in 6-, 12-, 24-, 48-, 96-, and 384-well plate formats. AID GmbH products are ISO 13485 certified and CE marked.

View more on https://www.aid-diagnostika.com/en/

AKOYA BIOSCIENCES

Akoya Biosciences offers comprehensive solutions for multiplexed immunofluorescence that span the journey from biomarker discovery to validation. Founded in 2015, Akoya has an exclusive license to commercialize the CODEX® benchtop platform which can image 40+ tissue biomarkers using existing fluorescence microscopes. In October 2018, Akoya Biosciences acquired the Phenoptics™ business of PerkinElmer, which includes the Vectra® Polaris™ system for high throughput multiplexed immunofluorescence.

View more on www.akoyabio.com

BIOZOL – Fit for Science

At BIOZOL we provide you borderless research and knowledge in the life sciences. Therefore, we are proud to support you with over 16 million products and services of well more than 100 life science suppliers around the world. Together with our highly qualified Scientific Support, BIOZOL is your One-Stop-Shop Solution for all life science areas.

View more on www.biozol.de

CeGaT

CeGaT is a leading global provider of genetic diagnostics and mutation-related disease analyses. The company combines its next-generation sequencing process and analysis pipelines with its medical expertise to support physicians and oncologists in choosing the optimal therapeutic strategy. CeGaT's tumor diagnostics portfolio provides a detailed analysis of causative mutations and determines TMB and MSI for therapeutic decisions on immunotherapies.

View more on https://www.cegat.de/en/

ENPICOM

ENPICOM is an innovative bioinformatics software engineering company with an outstanding team of professionals. We focus on supporting immunotherapy developers with groundbreaking products and customized solutions to improve and accelerate discovery and development of novel immunotherapies, and the stratification for, and monitoring of immunotherapies under development. Our first product on the market is world-class immunosequencing data analysis solution, the ImmunoGenomiX (IGX) platform. IGX is an innovative T-cell receptor and B-cell receptor repertoire analysis platform; for efficient management, storage, analysis and visualization of clone data.

View more on www.enpicom.com

FLUIDIGM

Fluidigm is committed to empowering the cancer immunotherapy community with research tools to interrogate the tumor microenvironment with unprecedented resolution. Whether you seek to target new biomarkers or to optimize the effectiveness of checkpoint inhibitors, CAR T cells or cancer vaccines, Fluidigm can help you reach your next research breakthrough.

View more on www.fluidigm.com

Immudex

Immudex is a Danish reagents and solutions provider for Immune monitoring. Based on their proprietary Dextramer® Technology, Immudex provides reagents superior for measurement of antigen-specific T cells. Immudex' dCODE™ Dextramer® Technology, compatible with 10x Genomics Feature Barcode Single Cell analysis, can unravel the specificity of the Immune system and allow a new understanding of immunological responses.

View more on http://www.immudex.com/

Indica Labs

Indica Labs' image analysis and collaborative image management software platforms, HALO, HALO-AI and HALO -Link, facilitate quantitative evaluation of digital pathology images. With unmatched ease-of-use, speed and scalability, pharmaceutical, healthcare and research organizations worldwide are using Indica Labs' software and services for high-throughput, quantitative tissue analysis in oncology, neuroscience, metabolism, and toxicology.

View more on www.indicalab.com

Metabolon Inc.

Metabolon, Inc. is the world's leading health technology company advancing metabolomics for precision medicine and life science research. Its Precision Metabolomics™ is a powerful technology for assessing health and delivering biomarker discoveries, innovative diagnostic tests, and valuable data for genomics and population health initiatives.

View more on https://www.metabolon.com

NanoString Technologies

NanoString® Technologies provides life science tools for translational research and molecular diagnostic products. The Company's proprietary nCounter® Analysis System offers simultaneous analysis of RNA, DNA, and protein expression with high sensitivity and precision. NanoString collaborates with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

View more on nanostring.com

OriGene Technologies

OriGene is your "1 stop solution provider". OriGene Technologies GmbH as European headquarter based in Germany, offers more than 1 million research products – everything you need for gene and protein based research: CRISPR, cDNA clones, siRNA, lysates, proteins, antibodies and many more. We support you as cancer research scientists in your gene as well as protein directed approaches.

View more on www.origene.com

Quanterix

Quanterix is digitizing biomarker analysis to advance the science of precision health. The company's digital health solution, Simoa®, has the potential to change today's approach to healthcare. Currently used in many therapeutic areas including oncology and immuno-oncology, Simoa is designed to enable earlier disease detection, better prognoses and enhanced treatment methods to improve quality of life and longevity for generations to come.

View more on www.quanterix.com

Society for Immunotherapy of Cancer (SITC)

The Society for Immunotherapy of Cancer (SITC) is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC serves scientists, clinicians, patients, patient advocates, government representatives and industry leaders from around the world. Currently, SITC has more than 2,400 members who represent 22 medical specialties in 42 countries around the world.

View more on sitcancer.org

Thermo Fisher Scientific

Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. Through our Invitrogen and Ion Torrent brands, we help customers accelerate innovation and enhance productivity.

View more on www.thermofisher.com

Ultivue

Ultivue provides multiplex biomarker assays for tissue phenotyping and digital pathology. Ultivue's InSituPlex® technology eliminates the need for assay development and optimization. UltiMapper™ I/O kits provide robust and reproducible results right out of the box for researchers to gain a deeper understanding of the tumor microenvironment.

View more on www.ultivue.com

ORGANIZING PARTNERS

THE MEET THE EXPERTS SESSION ON
"TNBC (TRIPLE NEGATIVE BREAST CANCER)" IS SUPPORTED BY
A MEDICAL EDUCATION GRANT FROM

Roche

SYMPOSIUM AGENDA

Friday, April 12, 2019 at 08.30 – 09.30 hrs

- TNBC (Triple Negative Breast Cancer) Meet the Expert Session
  Chair: Christoph Zielinski
- Predictive biomarkers for cancer immunotherapy in TNBC
  Luciana Molinero, San Francisco, CA, USA
- Cancer immunotherapy/PD-L1 checkpoint inhibitors in Advanced Triple-Negative Breast Cancer.
  Christoph Zielinski, Vienna, Austria
- Discussion

EXHIBITORS (PIPELINE) SESSION

SESSION AGENDA

Friday, April 12, 2019 at 12.45 – 13.15 hrs

12.45 - 13.15 **Exhibitors (Pipeline) Session**

Chair: Heinz Zwierzina

FLUIDIGM

"Define the Tumor Microenvironment with CyTOF® technology and microfluidics solutions" Fludigm enables the comprehensive cellular and molecular profiling of the immune system and the tumor microenvironment with proven mass cytometry, Imaging Mass Cytometry™ (IMC™) and automated microfluidics solutions.Whether you seek to target new biomarkers and pathways or to optimize the effectiveness of checkpoint inhibitors, CAR T cells or cancer vaccines, Fluidigm can help you identify new insights to reach your next research breakthrough.

Roberto Spada, Business Development Specialist, Mass Cytometry, Fluidigm

NANOSTRING

"Discovery of candidate predictive biomarkers for therapeutic response to immune checkpoint inhibitors in melanoma."
Significant progress has been made in the development of molecular diagnostics to predict therapeutic response to immune checkpoint inhibitors (ICI) in melanoma, however there remain many patients whose response is not accurately predicted. Stimulated by this challenge, we have collaborated with Dr. David Rimm at Yale University to evaluate the application of high plex spatially resolved protein analysis in FFPE specimens using GeoMx® Digital Spatial Profiling (DSP) to the discovery of candidate biomarkers for ICI response in melanoma. Using DSP, we have analyzed the spatial expression of 44 immune-related proteins across 60 ICI-treated patients. The expression patterns of a subset of the proteins were first validated through comparison to Quantitative Immunofluorescence. DSP analysis identified multiple markers that were predictive of prolonged progression free and/or overall survival. This study exemplifies the power of high-plex protein analysis in FFPE tumor specimens in the context of therapeutic response.

Douglas Hinerfeld, PhD. Principal Product Application Scientist. Nanostring Technologies

AKOYA BIOSCIENCES

Dr. Björn Wendik will discuss Akoya's portfolio of solutions for multiplexed immunofluorescence that span applications across biomarker discovery and clinical research. Attendees will get a quick overview of the latest enhancements to the Opal™ multiplex IHC kits, the Vectra® Polaris™ System and inForm™ software analysis package. Dr. Wendik will also give a quick overview of the CODEX® benchtop system which enables researches to image 40+ biomarkers in a tissue sample, using existing fluorescence microscopes.

Björn Wendik, PhD, Field Application Scientist, Akoya Biosciences, Inc.

Society for Immunotherapy of Cancer

Advancing the Science and Application of Cancer Immunotherapy

The Society for Immunotherapy of Cancer (SITC) is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC has more than 2,400 members representing 31 medical specialties in 40 countries, serving research scientists, physician scientists, clinicians, patients, patient advocates, government representatives and industry leaders. Through education programs that foster scientific exchange and collaboration, SITC aims to one day make the word "cure" a reality for cancer patients everywhere.

SITC resources include:

Discounted rate for SITC members

- **34th Annual Meeting & Pre-Conference Programs (SITC 2019)**
  - Nov. 6–10, 2019 at the Gaylord National Hotel & Convention Center in National Harbor, Md.
  - The leading destination for scientific exchange, education and networking in the cancer immunotherapy field
- ***Journal for ImmunoTherapy of Cancer*** **(JITC)**
  - SITC's open access, peer-reviewed online journal
  - 8.374 impact factor
  - SITC members receive a 60 percent discount on processing fees for all JITC articles submitted and accepted in 2019
- **SITC Cancer Immunotherapy CONNECT (sitcancer.org)**
  - **SITC CONNECT:** SITC's website for the latest news, research and community conversation related to cancer immunotherapy
  - **SITC connectED:** SITC's free, go-to source for online cancer immunotherapy education, featuring more than 80 educational classes and activities for researchers, clinicians and patients

Learn more at **sitcancer.org**

GENERAL INFORMATION

SECRETARIATS

SECRETARIAT
Cancer Drug Development Forum
c/o BLSI
Clos Chapelle-aux-Champs 30
1200 Brussels, Belgium

- Phone: +32 (0)2 775 02 15
- Email: info@cddf.org
- Website: www.cddf.org

CONFERENCE MATTERS

Vienna Medical Academy
Conference & Society Management

- Contact: Catherine Tomek
- E-mail: itoc@medacad.org
- Telephone: +43 1 405 13 83 18
- Website: www.medacad.org

SPONSORSHIP AND EXHIBITION MATTERS

Rose International
Exhibition Management & Congress Consultancy bv

- Contact: Flora van Laer
- E-mail: fvanlaer@rose-international.com
- Telephone: +31 70 383 8901

CONFERENCE VENUE

ERSTE CAMPUS
Am Belvedere 1
1100 Vienna, Austria

HOW TO REACH THE VENUE

The Erste Campus has an excellent connection to public transport.
Close by you will find the main train station (national & international train services, S Bahn lines S1, S2, S3, S60, S80) as well as the underground (U1) and the tram (O,D,18), busses (69A, 13A, N66) and the regional & international bus terminal.



REGISTRATION

	REGISTRATION HOURS
Thursday, April 11, 2019	09:00 - 18:30 hrs
Friday, April 12, 2019	07:30 - 18:00 hrs
Saturday, April 13, 2019	08:00 - 13:00 hrs

EXHIBITION OPENING HOURS

	EXHIBITION OPENING HOURS
Thursday, April 11, 2019	09:00 - 19:30 hrs
Friday, April 12, 2019	08:30 - 16:00 hrs
Saturday, April 13, 2019	08:30 - 14:00 hrs

Registration fees in Euro

PAYMENT RECEIVED	EARLY BIRD UNTIL DEC. 17, 2018	FROM DECEMBER 18 TO APRIL 1, 2019	ON-SITE
Academia	450,-	550,-	650,-
Junior Participant[1]	120,-	130,-	175,-
Industry	750,-	850,-	950,-
SITC Members – Academia[2]	380,-	480,-	580,-
SITC Member – Junior Participant[2]	100,-	130,-	155,-
Foundations & Charities	225,-	275,-	325,-
Press/Media Pass Registration[3]	No fee, but registration is mandatory		
Welcome Reception	No fee, but registration is mandatory		
Conference Dinner for registered participants	45,-		

[1] The "Junior Participant" registration is available for Students under 30 years of age. Please provide a copy of a student ID at the time of your registration.

[2] Please provide the SITC Promotional Code during onsite registration. Note: the reduced registration fee only applies if the code is provided – make sure to inquire with SITC prior to your onsite registration.

[3] A Press ID confirming your status must be provided at the time of your registration.

IMPORTANT:

Reduced registration fees are only applicable, if they have been credited to the congress account before the respective deadlines. Registering before a deadline without performing an actual payment was not sufficient to benefit from the reduction. Please note that a different fee applies for onsite payments and registrations. **If the fee is not transferred to the congress bank account before the respective deadline expires the fee will be changed to the next applicable fee automatically.**

What is covered by the registration fee?

- Admission to all scientific sessions
- Abstract book and programme
- Welcome reception (no fee but registration mandatory)
- Coffee breaks & Lunches
- Admission to exhibition

CANCELLATIONS

Please note that only written cancellations addressed to ITOC6 c/o Vienna Medical Academy, Alser Straße 4, 1090 Vienna, Austria either per E-Mail: itoc@medacad.org or Fax: +43 1 405 13 83 918 can be accepted.

The following rules apply:

- before January 31, 2019: 50% refund
- after January 31, 2019: no refund

REPLACEMENTS

Any replacement (i.e. change of delegate name) of a confirmed registration is subject to a EUR 50,- charge per participant.

BADGES

For security reasons, badges will be checked upon access of the conference areas. Delegates are therefore requested to wear their badge at all times during the conference.

CATERING

Coffee breaks, lunches and a welcome reception have been scheduled in the exhibition area. Exact times are listed in the programme overview.

CERTIFICATE OF ATTENDANCE

The 6th ImmunoTherapy of Cancer Conference is happy to introduce a digital CME acquisition system. You will be able to view and print a confirmation stating the according number of CME credits after finishing a survey requested by the UEMS. The link to the survey will be sent to all registered participants right after the conference. It is possible to claim a maximum of **15 CME** points for attendance of scientific sessions at the ITOC6.

EXHIBITION

The exhibition is held in the "Atrium" of the Erste Campus. Entrance is free for registered delegates but limited to healthcare professionals, press and exhibitors.

INSURANCE

By registering to the ITOC6, participants agree that neither the organising committee nor the congress office assume any liability whatsoever.

Participants are requested to make their own arrangements for health and travel insurance. The conference fee does not include insurance.

LANGUAGE & TRANSLATION

The official language of the conference is English. No simultaneous translation is provided.

LOST & FOUND

All enquiries should be directed to the registration desk. The organizers accept no responsibility for loss due to theft or negligence.

NETWORKING EVENTS

Thursday, April 11, 2019
Welcome Cocktail in the exhibition area of the venue Erste Campus
Time: 18.20 hrs
No fee for registered participants, but registration is mandatory!

Friday, April 12, 2019
Conference Dinner, Mayor's Reception
Heuriger Fuhrgassl-Huber
Neustift am Walde 68, 1190 Wien
Time: 19.30 hrs
Contribution towards expenses: EUR 45,-

POLICIES

ITOC6 is accessible to all registered delegates. Children and members of the public are not permitted in the exhibition area or any room hosting an industry activity. In addition, the ITOC6 conference asks delegates and faculty to refrain from taking children and accompanying adults to any sessions or practical demonstrations. In the event that children are required to enter the conference centre, they should be supervised by an adult at all times and observe the restrictions that apply to limited access areas. In the event that a member of public is invited to participate in the ITOC6 conference scientific programme, they should be accompanied by a qualified healthcare professional or ITOC6 representative observing the ITOC6 restrictions where appropriate.

NOTES

nanoString™

NanoString Presentation:

Discovery of Candidate Predictive Biomarkers for Therapeutic Response to Immune Checkpoint Inhibitors in Melanoma

Speaker: Douglas Hinerfeld, PhD
Principal Product Application Scientist,
NanoString Technologies

12 April 2019
12.55 – 13.05 hrs
in the main Lecture Hall



Introducing GeoMx™ Digital Spatial Profiler: Your GPS for Biology

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

MAR 2019 MK1405